Information Provided By: 
Fly News Breaks for January 28, 2020
XLRN
Jan 28, 2020 | 07:05 EDT
H.C. Wainwright analyst Edward White raised his price target for Acceleron Pharma to $90 from $88 after the company's Phase 2 placebo-controlled trial evaluating sotatercept for the treatment of patients with pulmonary arterial hypertension reached its primary and key secondary endpoints. The analyst believes the risk benefit ratio shows sotatercept could become a novel treatment option for PAH patients. He reiterates a Buy rating on the shares.
News For XLRN From the Last 2 Days
There are no results for your query XLRN
